Repare Therapeutics (NASDAQ:RPTX) Receives “Buy” Rating from HC Wainwright

Repare Therapeutics (NASDAQ:RPTX)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a report released on Friday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price objective would suggest a potential upside of 178.55% from the company’s previous close.

Separately, Lifesci Capital upgraded Repare Therapeutics to a “strong-buy” rating in a report on Monday, July 29th.

Repare Therapeutics Trading Up 2.9 %

Shares of RPTX opened at $3.59 on Friday. Repare Therapeutics has a twelve month low of $2.71 and a twelve month high of $8.49. The firm has a market capitalization of $152.38 million, a P/E ratio of -1.80 and a beta of 0.72. The firm’s 50-day moving average is $3.35 and its two-hundred day moving average is $3.40.

Institutional Investors Weigh In On Repare Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Vontobel Holding Ltd. raised its position in shares of Repare Therapeutics by 20.0% during the 3rd quarter. Vontobel Holding Ltd. now owns 24,000 shares of the company’s stock worth $83,000 after purchasing an additional 4,000 shares during the last quarter. XTX Topco Ltd acquired a new stake in Repare Therapeutics during the 2nd quarter valued at $110,000. Exchange Traded Concepts LLC increased its position in Repare Therapeutics by 21.2% during the third quarter. Exchange Traded Concepts LLC now owns 50,441 shares of the company’s stock worth $174,000 after buying an additional 8,809 shares in the last quarter. Opaleye Management Inc. acquired a new position in shares of Repare Therapeutics in the first quarter worth $318,000. Finally, Marshall Wace LLP purchased a new stake in shares of Repare Therapeutics in the second quarter valued at $273,000. 85.09% of the stock is currently owned by hedge funds and other institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics Inc, a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair.